Using an intragastric balloon to improve asthma control in obese patients
Intragastric Balloon in Obese Patients With Uncontrolled Asthma: a Multicentre Randomized Controlled Study
This study is testing if using an intragastric balloon can help obese patients with uncontrolled asthma manage their symptoms better when combined with diet and exercise changes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse, Occitanie) |
| Trial ID | NCT05364957 on ClinicalTrials.gov |
What this trial studies
This project investigates the impact of an intragastric balloon (IGB) on asthma management in obese patients who have uncontrolled asthma. Participants will be randomly assigned to receive either the IGB along with dietary and exercise interventions or just the dietary and exercise interventions alone. The primary outcome will be measured by the change in Asthma Control Questionnaire (ACQ) scores after one year. The study aims to address the complex relationship between obesity and asthma, particularly in patients who do not respond well to standard asthma treatments.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 18 to 65 with uncontrolled asthma and obesity, specifically those with a BMI between 30 and 40.
Not a fit: Patients with chronic obstructive pulmonary disease (COPD) or those who have recently been diagnosed with cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved asthma control and overall health for obese patients with uncontrolled asthma.
How similar studies have performed: While the relationship between obesity and asthma is well-documented, the use of an intragastric balloon for asthma control in this specific population is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men and women aged between 18 and 65 years 2. Asthma according to the Global Initiative for Asthma (GINA) criteria 3. Patients with uncontrolled asthma based on an ACQ score ≥1.5 despite inhaled corticosteroids ± long acting bronchodilators (LABA) 4. Patients with grade I obesity (BMI\> 30 kg/m² and \< 35 kg/m²) or morbid obesity (BMI\<40 or ≥35 kg/m² with serious physiological risks, as recommended by the French Health Authorities) with contraindications for or refusal of bariatric surgery. 5. Effective contraception for women 6. Patients who have signed a written informed consent form 7. Patients with health insurance 8. Complete COVID-19 vaccination schedule according to current guidelines Exclusion Criteria: 1. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) 2. Blood eosinophilia greater than 4.5 G/I 3. Treatment by biotherapy within the 12 months after inclusion 4. Cancer diagnosed within the last 5 years 5. Smoking \> 10 packs/year (PA) 6. One asthma exacerbation in the 4 weeks leading up to the inclusion visit or IGB placement. 7. Treatment with orlistat Xénical® or GLP1 analogues or regular consumption of narcotics (heroin, cocaine and amphetamines). Analgesic treatments, including level 3, are authorized during the study. 8. Any patient for whom IGB is contraindicated \[criteria defined by the French Society for Digestive Endoscopy) and the French Think-Tank for Hepato-Gastroenterology Practices\]: 8.1 Severe cognitive or psychiatric disorders, chronic alcoholism, drug addiction 8.2 Severe and unstabilised eating disorders: bulimia or history of anorexia 8.3 History of gastric surgery including the ring insertion 8.4 Haemostasis disorders 8.5 Anticoagulant or non-steroidal anti-inflammatory medicines 8.6 Severe liver disease 8.7 Pregnancy or desire to become pregnant or breastfeeding 8.8 Anticipated failure to comply with prolonged medical follow-up 8.9 Large hiatal hernias \> 5 cm, inflammatory (Crohn's) or stenosing small bowel disease, pyloric stenosis and structural abnormalities of the digestive tract 8.10 Systemic lupus erythematous 8.11 Severe oesophagitis and active gastroduodenal ulcer 8.12 Silicone allergy 9. Patient under guardianship or tutorship, persons placed under the protection of justice or persons participating in another search including an exclusion period still in progress
Where this trial is running
Toulouse, Occitanie
- University Hospital Toulouse — Toulouse, Occitanie, France (Recruiting)
Study contacts
- Principal investigator: Guilleminault M Laurent, MD — Study principal Investigator Toulouse University Hospital
- Study coordinator: Guilleminault Laurent, MD
- Email: guilleminault.l@chu-toulouse.fr
- Phone: 05 67 77 18 50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.